earnings
confidence high
sentiment neutral
materiality 0.65
10x Genomics reports preliminary Q4 rev $166M (+1% YoY); FY 2025 rev $642.8M incl. $44.1M settlements
10x Genomics, Inc.
2025-FY EPS reported
-$0.35
revenue$642,823,000
- Q4 consumables rev $141.7M (+6% YoY); Spatial consumables up 14% YoY to $41.0M.
- Q4 instruments rev $15.5M (-36% YoY); Single Cell instruments down 44% YoY.
- Full year rev ex-settlements $598.7M (-2% YoY); instruments rev down 39%.
- Cash & securities ~$520M at Dec 31, 2025; cumulative instruments: >6,400 Chromium, >1,500 Spatial.
- Single Cell consumables reactions sold increased >20% vs prior year.